Skip to main content

Cell Signaling Technology to Conduct Biomarker Study for Aventis

NEW YORK, Sept. 21 (GenomeWeb News) - Cell Signaling Technology said today that it has signed an agreement with Aventis to conduct a pilot study in which CST will identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase targets for Aventis.

 

Under the terms of the agreement, CST, based in Beverly, Mass., will use its PhosphoScan technology to identify the biomarkers, which may enable target validation and profiling assays to monitor kinase-targeted therapeutic pharmacodynamics and efficacy, CST said.

 

PhosphoScan, according to the company, is patent-pending phospho-proteomics technology that combines immunoaffinity purification and mass spectroscopy to determine cellular PTK phosphorylation profiles.

 

Financial terms of the deal were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.